This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lewis R. Baxter, Jr, MD; John C. Mazziotta, MD, PhD; Jorg J. Pahl, MD; Scott T. Grafton, MD; Peter St. George-Hyslop, MD; Jonathan L. Haines, PhD; James F. Gusella, PhD; Martin P. Szuba, MD; Carl E. Selin, MS; Barry H. Guze, MD; Michael E. Phelps, PhD

Arch Gen Psychiatry. 1992;49(2):148-154.

Abstract
• We examined chorea-free subjects at risk for Huntington's disease (n = 52) for lifetime psychiatric diagnoses, present mood, genetic marker status, and caudate glucose metabolic rates with positron emission tomography. Based on previous work, a caudate—ipsilateral hemisphere ratio less than 1.15 was defined as abnormal and predictive of Huntington's disease. None of three methods used to segregate subjects into groups more and less likely to develop Huntington's disease gave significant group rate differences for any formal psychiatric diagnoses. On present mood testing, however, subjective "anger/hostility" was significantly higher in those likely, compared with those less likely, to develop Huntington's disease, as determined by all three methods.

Author Affiliations
From the Departments of Psychiatry and Biobehavioral Sciences (Drs Baxter, Szuba, and Guze), Neurology (Drs Mazziotta and Grafton), and Radiological Sciences (Division of Nuclear Medicine and Biophysics) (Drs Baxter, Mazziotta, Pahl, Grafton, Guze, and Phelps and Mr Selin), and the Laboratory of Nuclear Medicine (Drs Baxter, Mazziotta, Pahl, Grafton, Guze, and Phelps and Mr Selin), UCLA School of Medicine; and Molecular Neurogenetics Laboratory, Massachusetts General Hospital, Boston (Drs St. GeorgeHyslop, Haines, and Gusella).

Footnotes
Accepted for publication May 6, 1991.

Presented in part at the annual meeting of the American College of Neuropsychopharmacology, Kaanapoli, Hawaii, December 13, 1989.

Reprint requests to Room 27-360, 760 Westwood Plaza, Los ANgeles, CA 90024 (Dr Baxter).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psychiatric disorders in preclinical Huntington's disease
Julien et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:939-943.
ABSTRACT | FULL TEXT  

Predictors of diagnosis in Huntington disease
Langbehn et al.
Neurology 2007;68:1710-1717.
ABSTRACT | FULL TEXT  

Specific Psychiatric Manifestations Among Preclinical Huntington Disease Mutation Carriers
Marshall et al.
Arch Neurol 2007;64:116-121.
ABSTRACT | FULL TEXT  

Chorea and related disorders
Bhidayasiri and Truong
Postgrad. Med. J. 2004;80:527-534.
ABSTRACT | FULL TEXT  

Neuropsychiatry of the basal ganglia
Ring and Serra-Mestres
J. Neurol. Neurosurg. Psychiatry 2002;72:12-21.
ABSTRACT | FULL TEXT  

Neuropsychiatry of Huntington's Disease and Other Basal Ganglia Disorders
Rosenblatt and Leroi
Psychosomatics 2000;41:24-30.
ABSTRACT | FULL TEXT  

Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
Harris et al.
Brain 1999;122:1667-1678.
ABSTRACT | FULL TEXT  

Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases: A Review of the Literature and Overview of Research Opportunities in Huntington's, Wilson's, and Fahr's Diseases
ANPA Committee on Research et al.
J. Neuropsychiatry Clin. Neurosi. 1998;10:249-266.
ABSTRACT | FULL TEXT  

Caudate Glucose Metabolic Rate Changes With Both Drug and Behavior Therapy for Obsessive-Compulsive Disorder
Baxter et al.
Arch Gen Psychiatry 1992;49:681-689.
ABSTRACT